Phase 2
As the late-stage trials continue to progress, Talaris is rapidly ramping up its resources and investments.
Treatment for non-alcoholic steatohepatitis (NASH), a severe form of fatty liver disease, consists mainly of lifestyle modification – specifically dieting and weight loss.
Thanksgiving week was marked by numerous clinical trial announcements. Here’s a look.
With the Thanksgiving holiday upon us, BioSpace felt it was important to give thanks for some of the positive things that have happened this year. And there are many!
Both Gilead Sciences and Merck announced they were pausing a Phase II trial of islatravir and lenacapavir in HIV.
A cardiovascular drug Pfizer licensed from Akcea Therapeutics in 2019 hit the mark in a Phase IIb dose-ranging study in patients with elevated non-HDL-C and triglycerides.
Tonix expects to begin enrollment in the trial for TNX-1900, an intranasal potentiated oxytocin, during the second half of 2022.
ARO-HSD will be evaluated in a Phase I/II trial that will assess the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of its ability to target HSD17B13 as a treatment for NASH.
Connect Biopharma shares plummeted 55% despite reported positive topline data from its Phase II trial of CBP-201 for adults with moderate-to-severe atopic dermatitis.
With the last full week before the Thanksgiving week in the U.S., companies had a fair amount of clinical trial news. Here’s a look.
PRESS RELEASES